Posters

      Pharmacokinetics of Nicotine and Subjective Effects Following the Single Use of a Non-Menthol and Menthol Version of Tobacco Heating System 2.2 in Two Studies in Japan: A Comparison with Single Use of a Combustible Cigarette and Nicotine Gum

      Picavet, P.; Haziza, C.; Baker, G.; Lama, N.; Ancerewicz, J. Ancerewicz.; Benzimra, M.; Nobuoka, F.; Sugimoto, M.; Lüdicke, F.

      Conference date
      Mar 23, 2015
      Conference name

      PMI-Hosted Poster Session
      Link to more information
      Topic
      Summary

      Introduction and Objectives: Philip Morris International is currently developing potentially reduced risk products (RRPs) with the intention to reduce the risk of tobacco-related diseases. The challenge indeveloping RRPs is two fold, i.e., developing tobacco products that are shown to reduce risk and that are acceptable to smokers as substitutes for combustible cigarettes (CC). The candidate RRP, the Tobacco Heating System (THS)2.2, tested in this study is heated at significantly lower temperatures than required for CC. The study reported here is part of a global clinical program and the objective of the study was to evaluate the plasma pharmacokinetic (PK) profile of nicotine following single use of THS2.2 menthol and non-menthol as compared to menthol and non-menthol combustible cigarettes (CC) and nicotine replacement therapy (NRT), respectively. Subjective effects were evaluated to get first insight to which extent adult smokers would find THS2.2 an acceptable substitute for CC.  

      Related Publications

      Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking

      Clinical

      Systematic review of the relation between smokeless tobacco and cancer of the pancreas in Europe and North America

      Clinical

      Reduced exposure to Harmful and Potentially Harmful Constituents after 90 days of use of Tobacco Heating System 2.2 Menthol in Japan: A comparison with continued cigarette use or smoking abstinence

      Clinical

      Reduced Exposure To Harmful And Potentially Harmful Constituents after 90 Days Of Use Of Tobacco Heating System 2.2 Menthol In Japan: A Comparison With Continued Cigarette Use Or Smoking Abstinence

      Clinical

      Psychometric Evaluation of the mCEQ applied to Cigarettes and Heat-Not-Burn Products in the US and Japan

      Clinical

      Pharmacokinetics Of Nicotine And Subjective Effects Following The Single Use Of A Non-Menthol And Menthol Version Of Tobacco Heating System 2.2 In Two Studies In Japan: A Comparison With Single Use Of A Combustible Cigarette And Nicotine Gum

      Clinical

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.